Chimerix (NASDAQ:CMRX) Rating Increased to Hold at StockNews.com

Chimerix (NASDAQ:CMRXGet Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Other equities research analysts have also recently issued reports about the company. Wedbush restated an “outperform” rating on shares of Chimerix in a research report on Monday, May 16th. HC Wainwright reduced their target price on shares of Chimerix from $24.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 16th. Maxim Group reduced their price objective on Chimerix to $6.00 and set a “na” rating on the stock in a research report on Tuesday, May 17th. Cowen decreased their target price on shares of Chimerix to $10.00 and set a “na” rating on the stock in a report on Tuesday, May 17th. Finally, Zacks Investment Research raised Chimerix from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 17th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $9.55.

NASDAQ CMRX traded up $0.22 during midday trading on Friday, hitting $1.99. 7,262,608 shares of the company traded hands, compared to its average volume of 2,189,227. The company’s 50-day simple moving average is $4.19 and its 200-day simple moving average is $5.31. Chimerix has a 52 week low of $1.57 and a 52 week high of $9.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.11 and a quick ratio of 3.11. The company has a market cap of $174.00 million, a PE ratio of -1.73 and a beta of 1.28.

Chimerix (NASDAQ:CMRXGet Rating) last posted its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.07. Chimerix had a negative net margin of 17,994.28% and a negative return on equity of 118.41%. During the same quarter in the prior year, the company earned ($0.18) EPS. On average, research analysts predict that Chimerix will post 1.58 earnings per share for the current year.

In other Chimerix news, CFO Michael T. Andriole bought 15,000 shares of the company’s stock in a transaction on Tuesday, May 17th. The shares were bought at an average price of $1.71 per share, for a total transaction of $25,650.00. Following the transaction, the chief financial officer now owns 212,724 shares of the company’s stock, valued at approximately $363,758.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders acquired a total of 36,400 shares of company stock worth $65,234 over the last quarter. Company insiders own 6.90% of the company’s stock.

Large investors have recently modified their holdings of the company. Engineers Gate Manager LP acquired a new position in Chimerix in the 1st quarter valued at about $54,000. E Fund Management Co. Ltd. purchased a new stake in shares of Chimerix during the first quarter worth about $59,000. Macquarie Group Ltd. raised its position in shares of Chimerix by 208.9% in the third quarter. Macquarie Group Ltd. now owns 10,400 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 7,033 shares during the last quarter. Ergoteles LLC purchased a new position in shares of Chimerix during the first quarter valued at approximately $65,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Chimerix during the first quarter worth approximately $66,000. Institutional investors and hedge funds own 62.76% of the company’s stock.

Chimerix Company Profile (Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Read More

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.